Alimera (ALIM) fell 29% in Thursday's AH trading after the FDA failed to approve its Iluvien...

|About: Alimera Sciences, Inc. (ALIM)|By:, SA News Editor

Alimera (ALIM) fell 29% in Thursday's AH trading after the FDA failed to approve its Iluvien drug and asked for more info, but Oppenheimer sees the weakness as a buying opportunity and expects Iluvien to eventually be approved.